Clinical Trials List
Protocol NumberHM-EMSI-301
Not yet recruiting
2018-05-01 - 2021-12-31
Phase III
Terminated2
-
Trial Applicant
PAREXEL INTERNATIONAL CO., LTD.
-
Sponsor
-
Trial scale
-
Update
2026/03/01
Investigators and Locations
Co-Principal Investigator
- Chong-Jen Yu Division of Hematology & Oncology
- 陳冠宇 Division of Hematology & Oncology
- Jih-Hsiang Lee Division of Hematology & Oncology
- JIN-YUAN SHIH Division of Hematology & Oncology
- Chia-Chi Lin Division of Hematology & Oncology
- CHAO-CHI HO CHAO-CHI HO Division of Hematology & Oncology
- 許嘉林 Division of Hematology & Oncology
- 林育麟 Division of Hematology & Oncology
- 林宗哲 Division of Hematology & Oncology
- 徐偉勛 Division of Hematology & Oncology
- 蔡子修 Division of Hematology & Oncology
- 廖唯昱 Division of Hematology & Oncology
- 吳尚俊 Division of Hematology & Oncology
- 楊景堯 Division of Hematology & Oncology
- 廖斌志 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 郭家佑 Division of Thoracic Medicine
- Ying-Ming Tsai Tsai Division of Thoracic Medicine
- 李玫萱 Division of Thoracic Medicine
- Jen-Yu Hung Division of Thoracic Medicine
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
55 participants
-
Global
530 participants
